Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tbc-3711
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
TBC-3711 is a next-generation, highly selective endothelin A receptor antagonist developed originally by Encysive Pharmaceuticals. It is a small molecule designed for oral and intravenous administration. The drug blocks the action of endothelin—a potent mediator of blood vessel constriction and smooth muscle growth in vascular walls—by selectively antagonizing the endothelin A receptor with over 100,000-fold selectivity versus the endothelin B receptor. This mechanism makes it more selective and potent than sitaxsentan sodium (THELIN), another drug from Encysive. TBC-3711 was investigated primarily for resistant hypertension and other cardiovascular disorders but development was discontinued after Phase II trials. Pfizer acquired Encysive Pharmaceuticals during its development[2][3][4][5].
- Other names
- Endothelin Mordulator 1
02
Targets
EDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on tbc-3711.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tbc-3711.